Cardiac diastolic abnormalities and atrial natriuretic factor in essential hypertension

R Pontremoli1, G P Bezante, C Robaudo

  • 1Department of Internal Medicine, University of Genoa, Italy.

Insights

Essential hypertension is linked to elevated atrial natriuretic factor (ANF) levels, particularly when cardiac diastolic function is impaired. This study explores the relationship between hypertension, ANF, and heart function.

Area of Science:

  • Cardiology
  • Endocrinology
  • Hypertension Research

Background:

  • Essential hypertension is a prevalent cardiovascular condition.
  • Atrial natriuretic factor (ANF) plays a role in cardiovascular homeostasis.
  • Understanding ANF regulation in hypertension is crucial for therapeutic development.

Purpose of the Study:

  • To investigate cardiac function and plasma ANF levels in patients with untreated essential hypertension.
  • To determine the correlation between ANF levels, blood pressure, and cardiac parameters.
  • To identify factors influencing ANF levels in hypertensive individuals.

Main Methods:

  • Studied 38 untreated hypertensive patients and 31 normotensive controls.
  • Measured plasma ANF levels and plasma renin activity (PRA).
  • Assessed cardiac function using echocardiography, including systolic and diastolic parameters.

Main Results:

  • Hypertensive patients had significantly higher ANF levels, correlated with mean arterial pressure and inversely with PRA.
  • Hypertensives exhibited normal systolic function but impaired diastolic function.
  • ANF levels were inversely correlated with left ventricular performance and directly with diastolic dysfunction in hypertensives.

Conclusions:

  • Impaired cardiac diastolic function is a significant determinant of elevated ANF levels in essential hypertension.
  • Both diastolic dysfunction and PRA influence ANF levels in hypertensive patients.
  • Findings suggest a link between cardiac structural and functional changes and neurohormonal activation in hypertension.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...